Such additional work may generate more nuanced knowledge of the glioblastoma TME and the interactions between anti-inflammatory TAMs, CD4+/CD8+ T cells and immune suppression, and is likely to yield novel therapeutic targets. This evidence concerns the gene CD8A and glioblastoma.